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Abstract: 
 
Eighteen (1–18) and seven (1, 4, 6–8, 17 and 18) compounds were isolated from organic extracts 
of axenic cultures of two freshwater fungi Clohesyomyces sp. and Clohesyomyces 
aquaticus (Dothideomycetes, Ascomycota), respectively. Compounds 1–12 belong to the α-
pyrone class of natural products, compounds 13 and 14 were tetrahydroxanthones, 
compounds 15 and 16 were hexahydroxanthones, while compounds 17 and 18 were 
cyclodepsipeptides. The structures were elucidated using a set of spectroscopic and spectrometric 
techniques. The absolute configurations of compounds 2, 3, 6, and 7 were assigned via a 
modified Mosher’s ester method using 1H NMR data. The relative configurations of 
compounds 14–16 were determined through NOE data. Compounds 1, 2, 6, 8, 13, 14, 
and 15 were found to inhibit the essential enzyme bacterial peptidyl-tRNA hydrolase (Pth1), with 
(13; secalonic acid A) being the most potent. Compounds 1 and 4–18 were also evaluated for 
antimicrobial activity against an array of bacteria and fungi but were found to be inactive. 
 
Keywords: Freshwater fungi | α-Pyrones | Tetrahydroxanthones | Cyclodepsipeptides | Bacterial 
peptidyl-tRNA hydrolase 
 
Article: 
 
1. Introduction 
 
In pursuit of structurally unique and bioactive secondary metabolites from distinct ecological 
habitats, our group has been interested in fungi, particularly freshwater fungi1, 2, 3, 4, 5 that inhabit 
submerged woody and herbaceous substrates in streams and lakes.6 Freshwater fungi represent a 
potentially rich, although poorly studied, source of new mycological and chemical diversity.7, 8 
 
While working in the Lake Brandt watershed of Greensboro, NC, two related freshwater fungal 
species, belonging to the genus Clohesyomyces, were isolated from submerged wood and 
accessioned as G100 and G102. Fungal strain G102 biosynthesized 18 compounds belonging to 
three distinct classes of natural products. Twelve were members of the α-pyrone class of 
secondary metabolites (1–12), of which five were known [phomopsinone A (1), phomopsinone B 
(2), phomopsinone C (3), pyrenocine M (4), and pyrenocine K (5)] and seven were new [6-
hydroxy-7-epi-phomopsinone A (6), 5-deoxy-7-hyrdoxypyrenocine M (7), pyrenocine P (8), 7-
hyrdoxypyrenocine M (9), pyrenocine Q (10), pyrenocine R (11), 5-hydroxyphomopsinone A 
(12)]. Alternatively, four metabolites were tetra/hexahydroxanthones (13–16), of which one was 
the known homodimeric tetrahydroxanthone, secalonic acid A (13), another was a new natural 
monomeric tetrahydroxanthone [8-hydroxyblennolide H (14)], and two were new monomeric 
hexahydroxanthones [cis-dihydro-8-hydroxyblennolide H (15) and trans-dihydro-8-
hydroxyblennolide H (16)]. Finally, also isolated were the two known cyclodepsipeptides [Sch 
378161 (17) and Sch 217048 (18)]. From the perspective of chemical mycology, it was 
interesting that of these 18 metabolites, the related strain G100 biosynthesized seven overlapping 
compounds, being 1, 4, 6–8, 17 and 18, which belong to the α-pyrone and cyclodepsipeptide 
classes of compounds, while the tetra/hexahydroxanthones were biosynthesized only by the 
G102 strain. Since these related fungi were isolated from the same freshwater habitat, and 
because they biosynthesized an overlapping series of compounds, the chemical, biological, and 
mycological data were combined into a single communication. 
 
α-Pyrones have been reported to have varying potency in assays for antifungal, antibacterial, and 
antialgal activity.9, 10 Tetrahydroxanthones are an important class of mycotoxins with diverse 
biological activities, including antitumor, antibacterial, and anti-HIV.11, 12, 13, 14, 15, 16, 17 The 
isolated cyclodepsipeptides in this study were reported as selective and competitive human 
tachykinin receptor (NK2) antagonists.18 Given this diversity of biological activities, 
compounds 1–18 were evaluated against a panel of bacteria and fungi. While in vivo activity was 
without prospect, in vitro inhibitory activity against the essential enzyme bacterial peptidyl-
tRNA hydrolase (Pth1) was observed. Bacterial Pth1 represents a promising new target for 
antibiotic development19 for which little is known about small molecule inhibition.20 Based on 
this initial screening set, secondary metabolites from fungal cultures could serve as a source of 
Pth1 inhibitors, providing avenues to better understand inhibitor binding and inhibitor bound 
states. 
 
2. Results and discussion 
 
The freshwater fungal strains, coded G100 and G102, were ITS sequenced21 and identified 
as Clohesyomyces aquaticus (Dothideomycetes, Ascomycota) and Clohesyomyces sp., 
respectively. Large-scale solid-phase cultures of G100 and G102 were extracted and partitioned 
with organic solvents, as described previously.3, 5 The organic extracts were then purified 
separately using normal-phase flash chromatography to generate five fractions each, which were 
then subjected to further purifications using preparative and semipreparative HPLC to yield 
seven (1, 4, 6–8, 17 and 18) and 18 compounds (1–18) from G100 and G102, respectively; all 
compounds were verified to have >95% purity as measured by UPLC using an evaporative light 
scattering detector (ELSD) (Fig. S1, Supporting Information). The biosynthetic potential of these 
two fungal cultures was broad, as compounds 1–12 belonged to the α-pyrone class of natural 
products, compounds 13–16were tetra/hexahydroxanthones, while compounds 17 and 18 were 
cyclodepsipeptides. 
 
 
Fig. 1. Structures of metabolites isolated from fungal cultures G100 and G102 (1–18). 
 
2.1. α-Pyrone derivatives 
 
The NMR and HRESIMS, along with CD and optical rotation data, where appropriate, identified 
compounds 1 [6.1 mg (G100); 27.8 mg (G102)]; 2 [0.8 mg (G102)], 3 [0.7 mg 
(G102)], 4 [0.8 mg (G100); 1.7 mg (G102)], and 5 [0.5 mg (G102)] as the known metabolites 
phomopsinone A,10 phomopsinone B,10 phomopsinone C,10 pyrenocine M,9 and pyrenocine 
K,9 respectively (Figs. 1 and S2–S6, Table S1). Compounds 1 and 4 were first isolated from two 
different strains of an endophytic Phomopsis sp., which were isolated from two different plant 
hosts.9, 10 The specific rotation data of 1 was not reported previously and hence provided herein. 
Epimeric 2 and 3 were first isolated from an endophytic Phomopsis sp., which was isolated 
from Santolina chamaecyparissus.10 The absolute configuration of 2 was determined by CD 
spectroscopy and TDDFT calculations.10 However, due to paucity and insufficient purity of 3, 
the researchers were unable to collect CD data to assign the absolute configuration. Hence, they 
relied on biogenetic considerations and the fact that 2 and 3 were epimers at C-10 to propose the 
absolute configuration for 3. No specific rotation data were reported for compounds 2 and 3. 
Herein, the absolute configurations of 2 and 3 were confirmed via a modified Mosher’s ester 
method (Fig. 2),22 the specific rotation data for 2 and 3 and the CD data for 3 were provided as 
well (Fig. 3). Finally, compound 5 was identified as the known pyrenocine K, which was first 
isolated from a Phomopsis sp., an endophyte of Cistus salviifolius.9 There were some minor 
differences between the reported and the collected NMR data for 5 (Table S2); however the 2D-
NMR and specific rotation data confirmed the structure of 5 as the known pyrenocine K.9 The 
NMR data are provided to update the literature (Table 1). CD data have not been reported for 
compound 5 and hence they are provided (Fig. 3) to confirm the absolute configuration as 7R. In 
short, the characterization data for five of the previously reported α-pyrones have been refined. 
 
 
Fig. 2. ΔδH values [Δδ (in ppm) = δS − δR] obtained for (S)- and (R)-MTPA esters A) 2a and 2b, 
respectively of phomopsinone B (2), B) 3a and 3b, respectively of phomopsinone C (3), 
C) 6a and 6b, respectively of 6-hydroxy-7-epi-phomopsinone A (6), and D) 7a and 7b, 
respectively of 5-deoxy-7-hyrdoxypyrenocine M (7) in pyridine-d5. 
 
Compound 6 [2.0 mg (G100); 1.2 mg (G102)] was obtained as a colorless solid with a molecular 
formula of C12H16O5 as determined by HRESIMS along with 1H, 13C, and edited-HSQC NMR 
data (Table 1, Table 2, Fig. S7), establishing an index of hydrogen deficiency of 5. The NMR 
data suggested that 6 was an α-pyrone analogue of 1. A key difference was replacement of the 
allylic methylene moiety (δH/δC 2.40/32.5, dd, J = 6.4, 1.8 for H2-6/C-6) in 1 by an oxymethine 
in 6 (δH/δC 4.21/66.6, dddd, J = 7.9, 2.9, 2.3, 1.7 for H-6/C-6). These data, along with a 16 amu 
difference in the HRMS data of compounds 1 and 6, indicated hydroxylation at the C-6 position 
in 6. The coupling constant (JH-6/H-7 = 7.9 Hz) implied a pseudoaxial/pseudoequatorial cis 
orientation in 6 (Table 1, Fig. S7). NOESY correlations observed between H-6 and H-7 indicated 
that these two protons were on the same face (Fig. 4). An HMBC correlation was observed from 
11-OCH3 to C-4, indicating the connectivity of the methoxy group (Fig. 5). HMBC correlations 
from H-3 to C-4, C-4a, and C-2, from H2-5 to C-6a and C-7, from H-6 to C-4a and C-8, from H-
7 to C-9, and from H3-10 to C-8 were observed (Fig. 5). The trivial name 6-hydroxy-7-epi-
phomopsinone A was ascribed to compound 6. The absolute configuration of 6 was assigned via 
a modified Mosher’s ester method,22 establishing the configurations as 6S and 7R (Fig. 2C), 
which were opposite to that reported for the known phomopsinone D.10 Moreover, 6-hydroxy-7-
epi-phomopsinone A (6) and phomopsinone D showed opposite CD spectra (Table S1, Fig. 3). 
The specific rotation data for phomopsinone D have not been reported in the literature 
previously. 
 
Fig. 3. ECD spectra of A) phomopsinone C (3) [0.58 mM] in CH3CN; B) pyrenocine K (5) 
[0.25 mM] in CH3OH; C) 6-hydroxy-7-epi-phomopsinone A (6) [0.12 mM] in CH3CN; D) 
pyrenocine P (8) [0.28 mM] in CH3OH; E) 5-hydroxyphomopsinone A (12) [0.13 mM] in 
CH3CN, and F) cis-dihydro-8-hydroxyblennolide H (15) [0.19 mM] and trans-dihydro-8-
hydroxyblennolide H (16) [0.22 mM] in CHCl3, cell length 2 cm. 
 
Table 1. 1H NMR Data (700 MHz) for 5 and (500 MHz) for 6, 8, and 12 in CDCl3.a 
Position 5 6 8 12 
3 5.43, s 5.48, s 5.45, s 5.44, s 
5 4.33, dt (14.9, 2.9) 4.38, dd (15.5, 2.3) 4.38, dtd (14.9, 2.9, 0.6) 5.87, d (4.0)  
4.52, dd (14.9, 1.2) 4.51, dd (15.5, 1.7) 4.63, ddd (14.9, 1.7, 0.6) 
 
6 2.47, m 4.21, dddd (7.9, 2.9, 2.3, 1.7) 2.38, dt (17.2, 2.9) 2.44, m  
2.52, m 
 
2.62, m 
 
7 4.12, m 3.48, ddd (8.7, 7.9, 2.9) 3.79, m 4.31, m 
8 2.60, dd (17.0, 4.7) 1.55, m 3.66, m 1.57, m  
2.85, dd (17.0, 7.3) 1.82, m 3.79, m 1.64, m 
9 
 
1.43, m 3.81, s 1.42, m   
1.58, m 
 
1.49, m 
10 2.20, s 0.95, t (7.5) 
 
0.95, t (7.5) 
11 3.79, s 3.82, s 
 
3.84, s 
5-OH 
   
2.81, d (4.0) 
6-OH 
 
2.68, d (2.9) 
  
8-OH 
  
2.04, t (6.3) 
 
aδ in ppm, mult (J in Hz). 
 
Table 2. 13C NMR Data for 5 and 10 (175 MHz) and for 6–9, 11–12 (125 MHz) in CDCl3.a 
Position 5 6 7 8 9 10 11 12 
2 164.2 163.8 164.6 164.1 164.3 165.4 164.1 163.8 
3 88.3 88.9 88.1 88.2 88.6 102.0 89.3 88.4 
4 168.5 168.2 171.0 168.4 170.1 165.9 170.8 168.6 
4a 107.6 109.1 108.9 107.6 113.7 92.9 108.6 108.9 
5 61.9 61.4 9.71 61.9 54.2 8.8 9.1 87.4 
6 32.3 66.6 38.9 28.3 38.5 71.4 59.3 32.6 
6a 155.9 155.9 158.2 155.9 161.9 165.0 157.0 160.1 
7 70.2 78.8 69.8 74.4 69.2 35.5 56.5 66.2 
8 48.9 34.3 39.5 64.9 40.0 27.4 
 
37.2 
9 205.7 18.7 18.9 56.2 18.9 22.6 
 
18.6 
10 31.2 14.1 14.1 
 
14.1 14.2 
 
14.05 
11 56.3 56.4 56.2 
 
56.6 56.6 
 
56.5 
aδ in ppm. 
 
Compound 7 [1.7 mg (G100); 0.7 mg (G102)] was obtained as a colorless solid with a molecular 
formula of C12H18O4 as determined by HRESIMS along with 1H, 13C, and edited-HSQC NMR 
data (Table 2, Table 3, Fig. S8), indicating an index of hydrogen deficiency of 4. These NMR 
data suggested another α-pyrone analogue with structural similarities to 1. However, a critical 
difference was replacement of the allylic oxymethylene moiety (δH/δC4.28/4.53/61.6, 
dt, J = 14.7, 2.8 and d, J = 14.7 for H-5a/H-5b/C-5) in 1 by a singlet methyl group 
in 7 (δH/δC 1.90/9.71). These data, along with a 2 amu difference in the HRMS data of 
compounds 1 and 7 and a decrease in hydrogen deficiency, indicated a cleavage of the 3,6-
dihydropyran ring in 7 relative to 1. HMBC correlations were observed from H3-5 to C-4 and C-
6a, from H2-6 to C-4a, C-6a, and C-8, from H3-10 to C-8, from 11-OCH3 to C-4, and from H-3 to 
C-4 and C-4a (Fig. 5). The trivial name 5-deoxy-7-hydroxypyrenocine M was ascribed to 
compound 7, and the absolute configuration was assigned as 7R via a modified Mosher’s ester 
method22 (Fig. 2). 
 
 
Fig. 4. Key NOESY correlations of 6, 12, and 14–16. 
 
 
 
Fig. 5. Key COSY and HMBC correlations of compounds 6–12 and 14–16. 
 
 
Table 3. 1H NMR Data (500 MHz) for 7 and 9–11 in CDCl3.a 
Position 7 9 10 11 
3 5.46, s 5.47, s 
 
5.50, s 
4a 
  
6.34, s 
 
5 1.90, s 4.30, d (12.6) 1.90, s 1.93, s   
4.51, d (12.6) 
  
6 2.62, dd (14.3, 4.0) 2.63, dd (14.3, 2.9) 4.42, m 4.46, d (6.3)  
2.69, dd (14.3, 8.6) 2.75, dd (14.3, 9.7) 
  
7 4.07, m 4.01, m 1.70, m 3.83, s    
1.87, m 
 
8 1.50, m 1.53, m 1.36, m 
 
   
1.42, m 
 
9 1.38, m 1.39, m 1.34, m 
 
 
1.50, m 1.46, m 
  
10 0.93, t (6.9) 0.94, t (7.5) 0.89, t (6.9) 
 
11 3.81, s 3.85, s 3.90, s 
 
5-OH 
 
3.29, br. 
  
6-OH 
  
2.02, d (5.7) 2.22, t (6.3) 
7-OH 
 
2.46, br. 
  
aδ in ppm, mult (J in Hz). 
 
Compound 8 [2.5 mg (G100); 2.4 mg (G102)] was obtained as a colorless solid with a molecular 
formula of C10H12O5 as determined by HRESIMS along with 1H, 13C, and edited-HSQC NMR 
data (Table 1, Table 2, Fig. S9), establishing an index of hydrogen deficiency of 5. These NMR 
data suggested 8 as an α-pyrone derivative with structural similarity to 1. Key differences were 
observed in the aliphatic side chain, where the terminal ethyl moiety in 1 was replaced by a 
hydroxy group in 8. These considerations, along with the COSY and HMBC data, established the 
structure of 8 (Fig. 5), which was confirmed via single crystal X-ray diffraction (Fig. 6); ECD 
data suggested the absolute configuration as 7S. The trivial name pyrenocine P was ascribed to 
compound 8. 
 
 
Fig. 6. X-ray crystallographic structure of 8. 
 
Compound 9 [6.9 mg (G102)], which was also obtained as a colorless solid, was found to have a 
molecular formula of C12H18O5 as determined by HRESIMS along with 1H, 13C, and edited-
HSQC NMR data (Table 2, Table 3, Fig. S10A), establishing an index of hydrogen deficiency of 
4. The structure of 9 was determined as an α-pyrone derivative by comparison of its NMR and 
HRMS data with those of 4. A key difference was replacement of the methylene moiety 
(δH/δC 1.68/27.9, m, H2-7/C-7) in 4 by an oxymethine in 9 (δH/δC4.01/69.2, m, for H-7/C-7). 
These data, along with a 16 amu difference in the HRMS data of compounds 4 and 9, indicated 
hydroxylation at C-7 in 9. HMBC correlations from H-3 to C-4, C-4a, and C-2, from H2-5 to C-
6a and C-4, from H2-6 to C-4a and C-8, from H2-9 to C-7, and from H3-10 to C-8 were observed 
(Fig. 5). The trivial name 7-hyrdoxypyrenocine M was ascribed to compound 9. In an attempt to 
determine the absolute configuration of 9 via a modified Mosher’s ester method,22 the compound 
was found to be racemic, suggesting that it may be an artifact of the purification processes (Fig. 
S10B). 
 
Compound 10 [0.7 mg (G102)] was obtained as a colorless solid with a molecular formula of 
C12H18O4 as determined by HRESIMS and analysis of 1H, 13C, and edited-HSQC NMR data 
(Table 2, Table 3, Fig. S11). Inspection of the NMR data suggested compound 10 as an α-pyrone 
analogue with structural similarity to 7, both sharing the same molecular formula. However, the 
allylic methyl singlet (δH/δC 1.90/9.71, s, for H3-5/C-5) in 7 was replaced by an olefinic proton 
(δH/δC 6.34/92.9, s, for H-4a/C-4a) in 10, and the olefinic proton (δH/δC 5.46/88.1, s, for H-3/C-3) 
in 7 was replaced by an allylic methyl singlet (δH/δC1.90/8.8, s, for H3-5/C-5) in 10. These data 
indicated that the olefinic proton and the methyl group switched positions, which was confirmed 
by observed HMBC correlations from H-4a to C-6 and C-6a (Fig. 5). Another key difference 
included a 1,2-hydroxy shift in 10 relative to 7. The allylic methylene moiety 
(δH/δH/δC 2.62/2.69/38.9, dd, J = 14.3, 4.0 and J = 14.3, 8.6, for H-6a/H-6b/C-6, respectively) 
in 7 was replaced by an allylic carbinol carbon (δH/δC4.42/71.4, m, for H-6/C-6), while the 
carbinol carbon (δH/δC 4.07/69.8, m, for H-7/C-7) in 7was replaced by a methylene moiety 
(δH/δH/δC 1.70/1.87/35.5, m, for H-7a/H-7b/C-7). This shift was confirmed by the observed 
HMBC correlations from 6-OH to C-6a and C-7, from H2-9 to C-7, and from H-6 to C-8 (Fig. 5). 
Further examination of the NMR data, including COSY and HMBC spectra (Fig. 5), yielded the 
structure of 10, which was ascribed the trivial name pyrenocine Q. As for 9, an attempt to 
determine the absolute configuration of 10 via a modified Mosher’s ester method22 revealed a 
racemic mixture of the R and Senantiomers. 
 
Compound 11 [0.5 mg (G102)] was isolated as a colorless solid with a molecular formula of 
C8H10O4 as revealed by analysis of the HRESIMS, 1H NMR, 13C NMR and edited-HSQC NMR 
data (Table 2, Table 3, Fig. S12), indicating an index of hydrogen deficiency of four. Inspection 
of the NMR data indicated 11 was a relatively simple α-pyrone derivative, but with differences 
in the aliphatic side chain and the 3,6-dihydropyran ring. In addition to key NMR resonances for 
the α-pyrone ring, NMR data indicated the presence of a methoxy group, an allylic methyl 
singlet and an allylic hydroxymethyl group (Table 2, Table 3, Fig. S12). These data suggested a 
trisubstituted α-pyrone derivative. HMBC correlations from H2-6 to C-4a, from H3-5 to C-6a, 
from H3-7 to C-4, and from H-3 to C-4a confirmed the substituents’ positions (Fig. 5). Further 
examination of the NMR data yielded the structure of 11, which was ascribed the trivial name 
pyrenocine R. 
 
Compound 12 [0.9 mg (G102)], which was isolated as a colorless solid, had a molecular formula 
of C12H16O5 as deduced from HRESIMS along with 1H NMR, 13C NMR, and edited-HSQC 
NMR data (Table 1, Table 3, Fig. S13), indicating an index of hydrogen deficiency of 5. 
Analysis of the NMR data indicated 12 as an α-pyrone derivative with structural similarity to 1. 
A key difference was replacement of the allylic oxymethylene moiety (δH/δH/δC 4.30/4.57/61.7, 
dt, J = 14.9, 2.9; d, J = 14.9, for H-5a/H-5b/C-5) in 1 by a dioxymethine group 
in 12 (δH/δC 5.87/87.4, d, J = 4.0, for H-5/C-5). These data, along with a 16 amu difference in the 
HRMS data of compounds 1 and 6, indicated hydroxylation at the C-5 position in 12, which was 
further confirmed by observation of an NMR signal for the -OH group (δH 2.81, d, J = 4.0) that 
showed diagnostic HMBC correlations with C-5 and C-4a (Table 3, Fig. 5). Further analysis of 
the NMR spectra, including COSY and HMBC data, yielded the structure of 12, which was 
given the trivial name 5-hydroxyphomopsinone A. The similarity of the ECD data of 12 (Fig. 3) 
with that of 1 (Fig. S2), along with the observed NOESY correlation from 5-OH to H-7, were 
used to establish the absolute configuration as 5R and 7S (Fig. 4). 
 
2.2. Monomeric/dimeric tetra/hexahydroxanthones 
 
Compounds 13–16 were identified as a homodimeric tetrahydroxanthone (13), a monomeric 
tetrahydroxanthone (14), and a pair of monomeric hexahydroxanthones (15–16). Analysis of 
HRMS, NMR, and ECD data identified 13 [7.4 mg (G102)] as the known secalonic acid A (Figs. 
S2 and S14).17, 23 Structurally related monomeric/dimeric tetrahydroxanthones, including 13, 
were isolated previously in our lab from an organic extract of the filamentous fungal 
culture Setophoma terrestris.17 
 
Table 4. 1H (500 MHz) and 13C NMR (125 MHz) for 14 and 16, and (100 MHz) for 15.a 
Position 14 15 16 
δC δH δC δH δC δH 
1 162.2 
 
162.1 
 
162.0 
 
2 110.9 6.52, d (8.0) 110.5 6.53, d (8.0) 110.7 6.53, d (8.6) 
3 138.3 7.35, dd (8.6, 8.0) 139.0 7.40, t (8.0) 139.2 7.40, dd (8.6, 8.0) 
4 108.1 6.55, d (8.6) 107.7 6.59, d (8.0) 107.9 6.54, d (8.0) 
4a 159.0 
 
160.3 
 
159.7 
 
5 77.1 3.90, d (10.9) 78.1 3.52, d (10.9) 79.2 3.76, dd (10.9, 3.4) 
6 29.4 2.40, m 28.5 2.26, m 31.7 1.84, m 
7 36.4 2.29, dd (19.5, 10.9) 39.7 1.53, ddd (14.3, 12.6, 2.9) 39.0 1.27, dd (13.2, 11.5)   
2.72, dd (19.5, 6.3) 
 
2.02, dt (14.3, 3.4) 
 
2.13, ddd (13.2, 5.2, 4.0) 
8 177.7 
 
67.9 4.37, d (4.0) 66.0 4.82, m 
8a 101.8 
 
52.4 3.12, d (4.0) 56.2 2.94, d (9.2) 
9 187.2 
 
196.9 
 
199.0 
 
9a 107.2 
 
109.8 
 
107.7 
 
10a 84.9 
 
85.0 
 
87.8 
 
11 18.2 1.15, d (6.3) 17.9 1.15, d (6.9) 18.3 1.11, d (6.3) 
12 170.5 
 
171.1 
 
169.3 
 
13 53.4 3.68, s 53.6 3.67, s 53.3 3.62, s 
1-OH 
 
11.23, s 
 
11.58, s 
 
11.12, s 
5-OH 
 
2.77, br. 
   
2.67, d (3.4) 
8-OH 
     
3.64, d (1.7) 
aδ in ppm, mult (J in Hz). 
 
Compound 14 [2.3 mg (G102)] was obtained as a colorless solid with a molecular formula of 
C16H16O6 deduced by HRESIMS and analysis of 1H NMR, 13C NMR and edited-HSQC NMR 
data (Table 4, Fig. S15), indicating an index of hydrogen deficiency of 9. Analysis of the HRMS 
and NMR data suggested 14 as a tetrahydroxanthone derivative with structural similarity to the 
monomeric units of 13. However, a key difference was replacement of the C-2 quaternary carbon 
in 13 (δC 118.3) by an aromatic methine in 14 (δH/δC 6.52/110.9, d, J = 8.0). COSY data 
identified two spin systems as H-2/H-3/H-4 and H-5/H-6/H2-7 (Fig. 5). Further examination of 
the NMR spectra, including HMBC data (Fig. 5), yielded the gross structure of 14, which was 
identical to the monomeric units of 13. A NOESY correlation was observed between 11-CH3 and 
H-5, indicating that those protons were on the same side of the molecule (Fig. 4). A proton 
doublet corresponding to H-5 (δH 3.90, d, J = 10.9 Hz) implied a pseudodiaxial trans orientation 
of H-5/H-6, as observed in the monomeric units of 13.17 These data along with biogenetic 
considerations established the relative configuration of 14 to be (5S,6R,10aS), the same as that of 
the monomeric units of 13. Due to the structural similarity of 14 with blennolide H, a 
tetrahydroxanthone derivative that has been recently isolated in our lab,17 compound 14 was 
ascribed the trivial name 8-hydroxyblennolide H. Moreover, compound 14 and blennolide H 
showed similar ECD spectra (Fig. S2), confirming the assignment of absolute configuration. 
Compound 14 was reported recently by synthesis and was described using the name (−)-
blennolide B.24 (−)-Blennolide B is an enantiomer of the natural blennolide B (which is dextro 
rotatory).25 Due to this confusion with the trivial name, and because this is the first isolation of 
the natural product, we believe that 10-hydroxyblennolide H is a more appropriate and 
understandable name. 
 
2.3. Cyclodepsipeptides 
 
In addition to compounds 1–16, two known cyclodepsipeptides, Sch 378161 (17) [4.6 mg 
(G100); 1.4 mg (G102)] and Sch 217048 (18) [10.7 mg (G100); 1.6 mg (G102)], were isolated 
and identified by means of NMR and HRMS and MS/MS data (Fig. S18), all of which compared 
favorably to the literature.18, 26 
 
2.4. Antimicrobial activity 
 
Compounds 1 and 4–18 were tested for antimicrobial activity against an array of bacteria and 
fungi (Staphylococcus aureus, Escherichia coli, Mycobacterium smegmatis, Candida albicans, 
and Aspergillus niger), but were found inactive. Compounds 1, 2, 6, 8, 13, 14, and 15 showed 
varying degrees of in vitro inhibition against bacterial Pth1 from several species. All but the most 
potent inhibitor lead to a decreased solubility of the enzyme under the conditions tested. A 
cloudiness in the reaction appeared upon addition of these compounds and was determined to be 
insoluble Pth1 from coomassie gel of the pelleted material after centrifugation. The degree of 
Pth1 aggregation was somewhat correlated to the amount of compound added, but also was 
effected by speed of compound addition, concentration of compound addition, temperature of the 
reaction, and was partially reversible over the course of the assay. Thus, while these compounds 
do appear to interact with Pth1, no meaningful quantitation of inhibition was possible. The most 
potent inhibitor was 13, demonstrating an IC50 of 1.4 mM against Salmonella typhimurium Pth1 
(Fig. 7). From chemical shift perturbation mapping, 13 was confirmed to bind in the active site 
(Fig. 8). Helping to explain the low affinity, 13 also bound to at least one other site on Pth1, in 
part the same secondary site which did not affect enzyme activity for a previously reported 
synthetic inhibitor.20 While not promising for clinical application, these findings represent the 
first reported small molecule natural product inhibitor of bacterial Pth1, which to date has been 
limited to crude natural product extracts.27, 28 Therefore these compounds provide tools to expand 
our understanding of Pth1 inhibition. With the tremendous structural biology knowledge of apo 
Pth1, having an inhibitor enables an array of follow-up structure-function studies, far out 
weighing the lack of potency. Of particular interest is high resolution structural characterization 
of an inhibitor bound complex, providing understanding of small molecule Pth1 inhibition, for 
which there is no substrate or inhibitor bound complex known to date. Also, having inhibitors 
with known structures provides a means to help bridge the gap between computational docking 
and empirical inhibition.29 
 
 
Fig. 7. Concentration-% inhibition curve of compound 13 against bacterial peptidyl-tRNA 
hydrolase (Pth1). 
 
 
Fig. 8. 1H-15N Chemical shift perturbations caused by 13 (secalonic acid A) binding to E. 
coli Pth1. At top, the ribbon diagram of E. coli Pth1 indicates residues with chemical shift 
perturbations between one third and one peak width in cyan and those greater than the peak 
width in blue. Catalytically essential His20 is red, with the side chain in the active site cleft 
shown. Below, the corresponding surface representations of Pth1 are colored as in part A. The 
cluster of perturbed residues (black arrow) indicate an interaction distinct from the Pth1 active 
site. 
 
3. Conclusions 
 
From two fungal cultures that were isolated from submerged wood in a lake, 18 compounds (1–
18) belonging to three structural classes, α-pyrone, tetra/hexahydroxanthones, and 
cyclodepsipeptides, were isolated and characterized. The studied fungi, G100 and G102, shared 
the ability to biosynthesize two classes of natural products, α-pyrone and cyclodepsipeptides. On 
the other hand, G102 has the additional biosynthetic capabilities to generate tetrahydroxanthone 
derivatives. The absolute configuration of the known (2 and 3) and the new (6 and 7) α-pyrone 
derivatives were assigned via a modified Mosher’s ester method. The relative configurations of 
the tetra/hexahydroxanthones (14–16) were determined through NOE data. Via testing these 
compounds against a new assay for inhibition of bacterial Pth1,30 the first natural product 
inhibitor (13) for this potential antibiotic target was identified. While target based screening for 
antibacterials has many well documented challenges,31 identification of Pth1 inhibitors opens the 
possibility for characterization of an inhibitor bound complex, which may, in turn, lead to more 
meaningful use of computational aspects aimed at inhibitor design/development. Interestingly, 
the dimeric tetrahydroxantione class of compounds, such as 13, seems to be attracting interest of 
the synthetic community.24 The current study is another demonstration4 that understudied 
biodiversity, regardless of its proximity to urban vs rural vs extreme locations, often reveals new 
chemical diversity. 
 
4. Experimental 
 
4.1. General experimental procedures 
 
Optical rotations, UV data, and ECD spectra were obtained using a Rudolph Research Autopol 
III polarimeter (Rudolph Research Analytical), a Varian Cary 100 Bio UV–vis 
spectrophotometer (Varian Inc.), and an Olis DSM 17 ECD spectrophotometer (Olis, Inc.). NMR 
data were collected using either a JEOL ECA-500 NMR spectrometer operating at 500 MHz 
for 1H and 125 MHz for 13C, or a JEOL ECS-400 NMR spectrometer operating at 400 MHz 
for 1H and 100 MHz for 13C and equipped with a high sensitivity JEOL Royal probe and a 24-
slot autosampler (both from JEOL Ltd.), or an Agilent 700 MHz NMR spectrometer (Agilent 
Technologies), equipped with a cryoprope, operating at 700 MHz for 1H and 175 MHz for 13C. 
Residual solvent signals were utilized for referencing. HRMS utilized a Thermo LTQ Orbitrap 
XL mass spectrometer equipped with an electrospray ionization source (Thermo Fisher 
Scientific). A Waters Acquity UPLC system (Waters Corp.) utilizing a Waters BEH C18 column 
(1.7 μm; 50 × 2.1 mm) was used to evaluate the purity of the isolated compounds with data 
collected and analyzed using Empower 3 software. Phenomenex Gemini-NX C18 analytical 
(5 μm; 250 × 4.6 mm), preparative (5 μm; 250 × 21.2 mm), and semipreparative (5 μm; 
250 × 10.0 mm) columns (all from Phenomenex) were used on a Varian Prostar HPLC system 
equipped with ProStar 210 pumps and a Prostar 335 photodiode array detector (PDA), with data 
collected and analyzed using Galaxie Chromatography Workstation software (version 1.9.3.2, 
Varian Inc.). Flash chromatography was performed on a Teledyne ISCO CombiFlash Rf 200 
using Silica Gold columns (both from Teledyne Isco) and monitored by UV and evaporative 
light-scattering detectors. Single crystal X-ray diffraction data were collected using a Bruker 
APEX CCD diffractometer (Mo Kα radiation, graphite monochromator). The crystallographic 
images were generated using CrystalMaker (CrystalMaker Software). All other reagents and 
solvents were obtained from Fisher Scientific and were used without further purification. 
 
4.2. Fungal strains isolation and identification 
 
Fungal strains G100 and G102 were isolated from conidia that were found on samples of 
submerged wood collected from Lake Brandt (36°10′01.0″N 79°50′18.0″W) in Greensboro, 
North Carolina, USA in October 2011. Collecting methods and culturing conditions utilized 
protocols outlined previously.32, 33, 34 Identifications were based on observation of 
micromorphological characters using an Olympus microscope (BX53) equipped with an 
Olympus DP25 camera. Molecular sequence data were obtained from internal transcribed spacer 
regions 1 & 2 and 5.8S nrDNA (ITS).21 DNA extraction, PCR amplification, and sequencing 
were performed using previously described methods.1, 2, 35 To obtain identification via sequence 
comparisons, the ITS region was BLAST searched against both GenBank and the UNITE 
databases.36 Results from BLAST search suggested sequence similarities between G100 and 
G102 to certain taxa within the order Pleosporales, Dothideomycetes, Ascomycota. G100 
showed similarity (94%) to Clohesyomyces aquaticus,37, 38 whereas, G102 showed similarity 
(98%) to Clohesyomyces sp. (MAFF 239218; GenBank: JQ435791). Interestingly, G100 was 
also morphologically identical to Clohesyomyces aquaticus (Fig. S20). The sequences with high 
homology were downloaded and analyzed using Maximum Likelihood39 to phylogenetically 
evaluate the evolutionary affinities of the two isolates (G100, and G102). Based on the results of 
morphology, BLAST search, and phylogenetic analysis of the ITS region, strain G100 was 
identified as Clohesyomyces aquaticus, while strain G102 was identified as having phylogenetic 
affinities to Clohesyomyces sp. (MAFF 239218; GenBank: JQ435791) (Fig. S19). The ITS 
sequences for both strains were deposited in the GenBank (G100: KM589855; G102: 
KU926856). Voucher cultures of strain G100 and G102 are maintained in the Department of 
Chemistry and Biochemistry culture collection at the University of North Carolina at 
Greensboro. 
 
4.3. Fermentation, extraction and isolation 
 
Extraction and fractionation of four fungal cultures of G100 and three fungal cultures of G102 
grown on rice, each weighing about 25 g, were performed as described previously.3 The organic 
defatted extract of G102 fungal culture (240 mg) was dissolved in CHCl3, adsorbed onto Celite 
545, and fractionated via normal-phase flash chromatography using a gradient solvent system of 
hexane–CHCl3–MeOH at a 30 mL/min flow rate and 61.0 column volumes over 34.1 min to 
afford five fractions. Fraction 2 (103.0 mg) was subjected to preparative HPLC using a gradient 
system of 40:60–80:20 of CH3CN–H2O (0.1% formic acid) over 15 min at a flow rate of 
21.24 mL/min to yield 6 sub-fractions. Sub-fractions 2 and 3 yielded compounds 1 (27.8 mg) 
and 14 (2.3 mg), which eluted at 11.2 min and 12.7 min, respectively. Fraction 3 (26.8 mg) was 
subjected to preparative HPLC using a gradient system of 30:70–80:20 of CH3CN–H2O (0.1% 
formic acid) over 30 min at a flow rate of 21.24 mL/min to yield 10 sub-fractions. Sub-fractions 
1, 2, 3, 4, 5, and 7 yielded compounds 5 (0.5 mg), 15 (0.6 mg), 16 (1.3 mg), 7 (2.8 mg), 10 
(0.7 mg), and 13 (7.4 mg), which eluted at 5.5 min, 6.6 min, 8.2 min, 11.0 min, 13.5 min, and 
25.7 min, respectively. Compounds 7 (2.8 mg) and 16 (1.3 mg) were subjected to further 
purification using semipreparative HPLC using a gradient system of 40:60–60:40 of CH3OH–
H2O (0.1% formic acid) over 15 min at a flow rate of 4.72 mL/min to yield compounds 7 (0.7 
mg) and 16 (1.0 mg), which eluted at 18.5 min and 12.6 min, respectively. Fraction 4 (37.5 mg) 
was subjected to preparative HPLC using a gradient system of 20:80–80:20 of CH3CN–H2O 
(0.1% formic acid) over 30 min at a flow rate of 21.24 mL/min to yield 12 sub-fractions. Sub-
fractions 1, 2, 6, 7, and 8 yielded compounds 8 (2.4 mg), 11 (1.0 mg), 12 (0.9 mg), 6 (1.2 mg), 
and 4 (1.7 mg), which eluted at 4.3 min, 5.0 min, 13.3 min, 15.5 min, and 16.5 min, respectively. 
Compound 11 (1.0 mg) was subjected to further purification using semipreparative HPLC using 
a gradient system of 20:80 to 40:60 of CH3OH–H2O (0.1% formic acid) over 15 min at a flow 
rate of 4.72 mL/min to yield compound 11 (0.5 mg), which eluted at 13.0 min. Sub-fractions 3 
(7.4 mg) and 4 (2.0 mg) were combined and subjected to preparative HPLC using an isocratic 
system of 20:80 of CH3CN–H2O (0.1% formic acid) at a flow rate of 21.24 mL/min to yield 
compounds 3 (0.7 mg), 9 (4.7 mg), and 2 (2.0 mg), which eluted at 43.0 min, 46.5 min, and 
53.5 min, respectively. Compound 2 (2.0 mg) was subjected to further purification using 
semipreparative HPLC using an isocratic system of 25:75 of CH3OH–H2O (0.1% formic acid) at 
a flow rate of 4.72 mL/min to yield compound 2(0.8 mg), which eluted at 38.0 min. Fraction 5 
(63.9 mg) was subjected to preparative HPLC using a gradient system of 20:80–80:20 of 
CH3CN–H2O (0.1% formic acid) over 30 min at a flow rate of 21.24 mL/min to yield 9 sub-
fractions. Sub-fractions 1, 3, and 5 yielded compounds 9 (2.2 mg), 17 (1.4 mg), and 18 (1.6 mg), 
which eluted at 7.9 min, 22.4 min, 24.3 min, respectively. 
 
In an analogous manner, the organic defatted extract of G100 fungal culture (170 mg) was 
dissolved in CHCl3, adsorbed onto Celite 545, and fractionated via normal-phase flash 
chromatography using a gradient solvent system of hexane–CHCl3–MeOH at a 30 mL/min flow 
rate and 61.0 column volumes over 34.1 min to afford five fractions. Extensive preparative and 
semipreparative HPLC purifications of fractions 2–5 yielded compounds 1 (6.1 mg), 4 (0.8 mg), 
6 (2.0 mg), 7 (1.7 mg), 8 (2.5 mg), 17 (4.6 mg), and 18 (10.7 mg). 
 
4.3.1. Phomopsinone A (1) 
 
Colorless solid; [α]D24 = +121° (c = 0.18, MeOH); CD (c 2.23 × 10−4 M, CH3CN) λ (Δε) 287 
(+14.9) nm, 264 (+10.7) nm, 237 (+10.4) nm, 210 (−49.7) nm; HRESIMS m/z 225.1118 
[M+H]+ (calcd for C12H17O4 225.1121). 
 
4.3.2. Phomopsinone B (2) 
 
Colorless solid; [α]D24 = +28.3° (c = 0.09, MeOH); HRESIMS m/z 241.1070 [M+H]+ (calcd for 
C12H17O5 241.1071). 
 
4.3.3. Phomopsinone C (3) 
 
Colorless solid; [α]D24 = +42.9° (c = 0.06, MeOH); CD (c 5.83 × 10−4 M, CH3CN) λ (Δε) 294 
(+7.5) nm, 271 (+6.8) nm, 250 (+7.1) nm, 214 (−13.4) nm, 207 (+16.5) nm, 200 (−24.5) nm; 
HRESIMS m/z 241.1070 [M+H]+ (calcd for C12H17O5 241.1071). 
 
4.3.4. Pyrenocine K (5) 
 
Colorless solid; [α]D24 = +43.8° (c = 0.05, MeOH); CD (c 2.52 × 10−4 M, CH3OH) λ (Δε) 300 
(4.5) nm, 272 (8.5) nm, 246 (5.7) nm, 230 (12.1) nm, 223 (27.2) nm; 1H NMR (CDCl3, 
500 MHz) and 13C NMR (CDCl3, 125 MHz), see Table 1, Table 2; HRESIMS m/z 239.0915 
[M+H]+ (calcd for C12H15O5 239.0914). 
 
4.3.5. 6-Hydroxy-7-epi-phomopsinone A (6) 
 
Colorless solid; [α]D24 = +56.4° (c = 0.08, MeOH); UV (MeOH) λmax (log ε) 285 (3.41), 212 
(3.28) nm; CD (c 1.25 × 10−4 M, CH3CN) λ (Δε) 209 (−67.4) nm, 225 (−10.1) nm, 233 
(−8.4) nm; 282 (+20.8) nm; 1H NMR (CDCl3, 500 MHz) and 13C NMR (CDCl3, 125 MHz), 
see Table 1, Table 2; HRESIMS m/z 241.1071 [M+H]+ (calcd for C12H17O5 241.1071). 
 
4.3.6. 5-Deoxy-7-hyrdoxypyrenocine M (7) 
 
Colorless solid; [α]D24 = −38.4° (c = 0.11, MeOH); UV (MeOH) λmax (log ε) 285 (3.25), 212 
(3.22) nm; 1H NMR (CDCl3, 500 MHz) and 13C NMR (CDCl3, 125 MHz), see Table 1, Table 2; 
HRESIMS m/z 227.1278 [M+H]+ (calcd for C12H19O4 227.1278). 
 
4.3.7. Pyrenocine P (8) 
 
Colorless solid; [α]D24 = +78.2° (c = 0.11, MeOH); UV (MeOH) λmax (log ε) 282 (3.43), 214 
(3.25) nm; 1H NMR (CDCl3, 500 MHz) and 13C NMR (CDCl3, 125 MHz), see Table 1, Table 2; 
HRESIMS m/z 213.0756 [M+H]+ (calcd for C10H13O5 213.0758). 
 
4.3.8. (±)-7-Hyrdoxypyrenocine M (9) 
 
Colorless solid; UV (MeOH) λmax (log ε) 283 (3.36), 213 (3.33) nm; 1H NMR (CDCl3, 500 MHz) 
and 13C NMR (CDCl3, 125 MHz), see Table 2, Table 3; HRESIMS m/z 243.1229 [M+H]+ (calcd 
for C12H19O5 243.1227). 
 
4.3.9. (±)-Pyrenocine Q (10) 
 
Colorless solid; UV (MeOH) λmax (log ε) 246 (3.25), 212 (3.08) nm; 1H NMR (CDCl3, 500 MHz) 
and 13C NMR (CDCl3, 175 MHz), see Table 2, Table 3; HRESIMS m/z 227.1275 [M+H]+ (calcd 
for C12H19O4 227.1278). 
 
4.3.10. Pyrenocine R (11) 
 
Colorless solid; UV (MeOH) λmax (log ε) 284 (2.93), 211 (3.04) nm; 1H NMR (CDCl3, 500 MHz) 
and 13C NMR (CDCl3, 125 MHz), see Table 2, Table 3; HRESIMS m/z 171.0650 [M+H]+ (calcd 
for C8H11O4 171.0652). 
 
4.3.11. 5-Hydroxyphomopsinone A (12) 
 
Colorless solid; [α]D24 = −4.5° (c = 0.07, MeOH); UV (MeOH) λmax (log ε) 280 (3.45), 213 
(3.28) nm; 1H NMR (CDCl3, 500 MHz) and 13C NMR (CDCl3, 125 MHz), see Table 2, Table 3; 
HRESIMS m/z 241.1071 [M+H]+ (calcd for C12H17O5 241.1070). 
 
4.3.12. 8-Hydroxyblennolide H (14) 
 
Colorless solid; [α]D24 = −113.3° (c = 0.11, MeOH); UV (MeOH) λmax (log ε) 334 (3.26), 277 
(3.36), 222 (3.46) nm; CD (c 1.56 × 10−4 M, CHCl3) λ (Δε) 379 (−14.4) nm, 328 (−23.4) nm, 293 
(−19.4), 248 (−43.3), 236 (+52.1), 226 (−126.2) nm; 1H NMR (CDCl3, 500 MHz) and 13C NMR 
(CDCl3, 125 MHz), see Table 4; HRESIMS m/z 321.0968 [M+H]+ (calcd for 
C16H17O7 321.0969). 
 
4.3.13. cis-Dihydro-8-hydroxyblennolide H (15) 
 
Colorless oil; [α]D24 = −72.7° (c = 0.09, MeOH); UV (MeOH) λmax (log ε) 354 (3.18), 276 (3.55), 
222 (3.53) nm; CD (c 1.86 × 10−4 M, CHCl3) λ (Δε) 344 (−2.2) nm, 274 (+45.0) nm, 237 
(+87.1) nm, 225 (−113.6) nm; 1H NMR (CDCl3, 500 MHz) and 13C NMR (CDCl3, 100 MHz), 
see Table 4; HRESIMS m/z 323.1117 [M+H]+ (calcd for C16H19O7 323.1125). 
 
4.3.14. trans-Dihydro-8-hydroxyblennolide H (16) 
 
Colorless oil; [α]D24 = +38.2° (c = 0.08, MeOH); UV (MeOH) λmax (log ε) 349 (3.13), 272 (3.48), 
222 (3.48) nm; CD (c 2.17 × 10−4 M, CHCl3) λ (Δε) 344 (+6.9) nm, 274 (−54.9) nm, 237 
(−18.4) nm, 225 (+22.1) nm; 1H NMR (CDCl3, 500 MHz) and 13C NMR (CDCl3, 125 MHz), 
see Table 4; HRESIMS m/z 323.1126 [M+H]+ (calcd for C16H19O7 323.1125). 
 
4.3.15. Preparation of the (R)- and (S)-MTPA ester derivatives of phomopsinone B (2), 
phomopsinone C (3), 6-hydroxy-7-epi-phomopsinone A (6) and 5-deoxy-7-hyrdoxypyrenocine 
(7) 
 
To 0.13, 0.15, 0.20 and 0.15 mg of compounds 2, 3, 6 and 7 were added 400 μL of pyridine-
d5 and transferred into NMR tubes. To initiate the reactions, 10 μL of S-(+)-α-methoxy-α-
(trifluoromethyl)phenylacetyl (MTPA) chloride were added into each tube with careful shaking 
and then monitored immediately by 1H NMR at the following time points 5, 10, 15, and 30 min. 
The reactions completed within 5, 5, 30 and 5 min, respectively, yielding the mono (R)-MTPA 
ester derivatives (2b) of 2, (3b) of 3, (6b) of 6, and (7b) of 7. 1H NMR data (500 MHz, pyridine-
d5) of 2b: δH 4.31 (1H, d, J = 14.9, H-5a), 4.61 (1H, d, J = 14.9, H-5b), 1.83 (2H, m, H2-8), 5.62 
(1H, m, H-9), 1.30 (3H, d, J = 5.7, H3-10); of 3b: δH 4.15 (1H, d, J = 14.9, H-5a), 4.52 (1H, 
d, J = 14.9, H-5b), 2.08 (1H, m, H-6a), 2.33 (1H, m, H-6b), 1.75 (1H, m, H-8a), 5.52 (1H, m, H-
9), 1.38 (3H, d, J = 6.3, H3-10); of 6b: δH 5.68 (1H, s, H-3), 4.32 (1H, d, J = 14.9, H-5a), 4.49 
(1H, d, J = 14.9, H-5b), 5.99 (1H, d, J = 6.9, H-6), 1.45 (1H, m, H-9a), and 0.88 (3H, t, J = 7.5, 
H3-10); of 7b: 5.79 (1H, s, H-3), 1.84 (3H, s, H3-5), 2.82 (1H, dd, J = 14.9, 5.2, H-6a), 3.03 (1H, 
dd, J = 14.9, 8.6, H-6b), 5.64 (1H, m, H-7), 1.60 (1H, m, H-8a), 1.69 (1H, m, H-8b), 1.23 (1H, 
m, H-9a), and 0.76 (3H, t, J = 7.5, H3-10). In an analogues manner, 0.13, 0.15, 0.20 and 0.15 mg 
of 2, 3, 6 and 7 dissolved in 400 μL pyridine-d5 were reacted in NMR tubes with 10 μL (R)-(−)-
a-MTPA chloride for 30 and 5 min, respectively, to afford the mono (S)-MTPA esters 
(2a, 3a, 6a and 7a). 1H NMR data (500 MHz, pyridine-d5) of 2a: δH 4.21 (1H, d, J = 14.9, H-5a), 
4.57 (1H, d, J = 14.9, H-5b), 1.79 (2H, m, H-8), 5.60 (1H, m, H-9), 1.37 (3H, d, J = 6.3, H3-10); 
of 3a: δH 4.26 (1H, d, J = 14.9, H-5a), 4.57 (1H, d, J = 14.9, H-5b), 2.14 (1H, m, H-6a), 2.44 
(1H, m, H-6b), 1.79 (1H, m, H-8a), 5.59 (1H, m, H-9), 1.29 (3H, d, J = 6.3, H3-10); 
of 6a: δH 5.74 (1H, s, H-3), 4.30 (1H, d, J = 14.9, H-5a), 4.51 (1H, d, J = 14.9, H-5b), 6.03 (1H, 
d, J = 6.9, H-6), 1.35 (1H, m, H-9a), and 0.83 (3H, t, J = 7.5, H3-10); of 7b: 5.73 (1H, s, H-3), 
1.62 (3H, s, H3-5), 2.70 (1H, dd, J = 14.9, 4.0, H-6a), 2.96 (1H, dd, J = 14.9, 8.6, H-6b), 5.66 
(1H, m, H-7), 1.64 (1H, m, H-8a), 1.76 (1H, m, H-8b), 1.35 (1H, m, H-9a), and 0.83 (3H, 
t, J = 7.5, H3-10). 
 
4.4. X-ray crystallography 
 
Crystallographic data for compound 8 has been deposited with the Cambridge Crystallographic 
Data Centre, deposition number CCDC 1473567. Compound’s 8 crystals were grown in MeOH 
at rt. X-ray crystal structure analysis of 8 were as follows: formula C10H12O5, MW = 212.20, 
irregular, colorless crystal, approximate dimensions 
0.28 × 0.24 × 0.13 mm, a = 4.1747 (3) Å, b = 10.9965 (7) Å, c = 11.0671 (7) Å, α = 70.466 (1)°, 
β = 85.814 (1)°, γ = 80.816 (1)°, T = 193 K, Z = 2, 
triclinic P1, GOF = S = 1.03, V = 472.57 (5) Å3, Rint (5123 reflections, I > 2σ(I)) = 0.019, 
wR(F2) = 0.099, λ = 0.71073 Å. Crystal data, data collection, structure solution and refinement 
details are summarized in Table S2. 
 
4.5. Bioassay methods 
 
Pth1 from Escherichia coli, Salmonella typhimurium and Pseudomonas aeruginosa was 
expressed and purified as described previously.40, 41 Inhibition was determined using established 
procedures.28, 30 Briefly quantification of bulk peptidyl-tRNA cleavage to free tRNA was 
quantified using electrophoretic separation via acid-urea gel to determine inhibitory activity of 
compounds under study. 
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Figure S1. UPLC chromatograms of compounds 1–18 (ELSD detection), demonstarting >95% purity. All 
data were acquired via an Acquity UPLC system with a BEH C18 (1.7 μm 2.1 × 50 mm) column and a 
CH3CN–H2O gradient that incresaed linearly from 20 to 100% CH3CN over 4.5 min. 
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Figure S1 cont. UPLC chromatograms of compounds 1–18 (ELSD detection), demonstarting >95% purity. 
All data were acquired via an Acquity UPLC system with a BEH C18 (1.7 μm 2.1 × 50 mm) column and a 
CH3CN–H2O gradient that incresaed linearly from 20 to 100% CH3CN over 4.5 min. 
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Figure S2. ECD spectra of A) phomopsinone A (1) [0.22 mM] in MeCN, B) phomopsinone B (2) [0.33 mM] 
in MeCN, C), and C) secalonic acid A (13) [0.03 mM] in CHCl3, D) 8-hydroxyblennolide H (14) [0.16 mM] 
in CHCl3, and E) blennolide H [0.43 mM] in MeOH, cell length 2 cm. 
 
 
  
4 
Table S1. CD data, experimental vs. literature, of phomopsinone A (1), phomopsinone B 
(2), 6-hydroxy-7-epi-phomopsinone A (6), and phomopsinone D. 
Compound 
CD: Conc. Solvent;  λmax (Δε) 
nm 
CD: Solvent;  λmax (∆ε/M–1cm–1) 
nm 
Experimental Literature 
Phomopsinone A (1) 
2.23 × 10–4 M, CH3CN 
283 (+14.3), 264 (+10.7), 238 
(+9.7), 221 (0), 213 (–48.6), 210 
(–49.7), 202 (+11.8) nm 
CH3CN: λmax (∆ε/M–1cm–1) = 
283 (+0.48), 238 (+0.88), 223 (0), 
213 (–4.17), 209 (0), 202 (+11.8) 
nma 
Phomopsinone B (2) 
3.33 × 10–4 M, CH3CN 
387 (+6.2), 232 (+5.9), 220 
(+0.7), 213 (–38.4), 209 (–62.4), 
203 (+29.3) nm 
 
CH3CN: λmax (∆ε/M–1cm–1) = 
284 (+0.49), 238 (+0.48), 222 (0), 
213 (–1.86), 209 (0), 201 (+5.11) 
nma 
6-hydroxy-7-epi-
phomopsinone A (6) 
1.25 × 10–4 M, CH3CN 
282 (+20.8), 251 (–0.37), 233 (–
8.4), 225 (–10.1), 209 (–67.4), 
202 (+28.8)  
---- 
Phomopsinone D ----- 
CH3CN: λmax (∆ε/M–1cm–1) = 
283 (–1.73), 253 (0), 236 (+1.32), 
216 (–0.31), 202 (+8.95), 190 (0) 
nma 
aHussain, H.; Krohn, K.; Ahmed, I.; Draeger, S.; Schulz, B.; Pietro, S.; Pescitelli, G. Phomopsinones 
A-D: Four new pyrenocines from endophytic fungus Phomopsis sp. Eur. J. Org. Chem. 2012, 1783-
1789. 
 
 
  
 
Table S2. NMR data for 5 and pyrenocine K (700 MHz for 1H, 175 MHz 
for 13C; chemical shifts in ppm, coupling constants in Hz, CDCl3). 
position 5 pyrenocine K
a 
δC, type δH mult (J in Hz) δC, type δH mult (J in Hz) 
2 164.2  163.9  
3 88.3 5.43, s 88.1 5.46, s 
4 168.5  168.3  
4a 107.6  107.3  
5 61.9 4.33, dt (14.9, 2.9) 61.6 4.25 dd (14.5, 2.0) 
  4.52, dd (14.9, 1.2)  4.53 d (14.5) 
6 32.3 2.47, m 33.3 2.45 m 
  2.52, m  2.55 m 
6a 155.9  155.7  
7 70.2 4.12, m 69.5 4.01 m 
8 48.9 2.60, dd (17.0, 4.7) 48.6 2.62 dd (14.0, 4.0) 
  2.85, dd (17.0, 7.3)  2.84 dd (14.0, 4.0) 
9 205.7  205.4  
10 31.2 2.20, s 32.0 2.20, s 
11 56.3 3.79, s 56.0 3.81, s 
a Hussain, H.; Ahmed, I.; Schulz, B.; Draeger, S.; Krohn, K. Fitoterapia 
2012, 83, 523-526. 
Rows highlighted in yellow show the chemical shift difference between 
compound 5 and those reported for pyrenocine K by Hussain et al, 2012. 
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Figure S3. 1H and 13C NMR spectra of compound 1 [400 MHz for 1H and 100 MHz for 13C, CDCl3]. 
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Figure S4. 1H NMR spectra of compounds 2 (upper panel) and 3 (lower panel) [500 MHz, CDCl3].  
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Figure S5. 1H and 13C NMR spectra of compound 4 [500 MHz for 1H and 125 MHz for 13C, CDCl3].  
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Figure S6. 1H and 13C NMR spectra of compound 5 [700 MHz for 1H and 175 MHz for 13C, CDCl3].  
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 Figure S7. 1H and 13C NMR spectra of compound 6 [500 MHz for 1H and 125 MHz for 13C, CDCl3].  
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Figure S8. 1H and 13C NMR spectra of compound 7 [500 MHz for 1H and 125 MHz for 13C, CDCl3].  
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Figure S9. 1H and 13C NMR spectra of compound 8 [500 MHz for 1H and 125 MHz for 13C, CDCl3].  
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Figure S10A. 1H and 13C NMR spectra of compound 9 [500 MHz for 1H and 125 MHz for 13C, CDCl3]. 
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Figure S10B. 1H NMR spectra of compound 9 (upper panel), and after reacting with S-(+)-α-methoxy-α-(trifluoromethyl)phenylacetyl (MTPA) 
chloride and (R)-(–)-a-MTPA chloride (middle and lower panels) [500 MHz, Pyridine-d5], showing the generation of two diastereoisomers per 
reaction.  
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  Figure S11. 1H and 13C NMR spectra of compound 10 [500 MHz for 1H and 175 MHz for 13C, CDCl3]. 
 
 
 
 
 Figure S12. 1H and 13C NMR spectra of compound 11 [500 MHz for 1H and 125 MHz for 13C, CDCl3]. 
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 Figure S13. 1H and 13C NMR spectra of compound 12 [500 MHz for 1H and 125 MHz for 13C, CDCl3]. 
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Figure S14. 1H and 13C NMR spectra of compound 13 [500 MHz for 1H and 125 MHz for 13C, CDCl3]. 
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Figure S15. 1H and 13C NMR spectra of compound 14 [500 MHz for 1H and 125 MHz for 13C, CDCl3]. 
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 Figure S16. 1H and 13C NMR spectra of compound 15 [500 MHz for 1H and 100 MHz for 13C, CDCl3]. 
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Figure S17. 1H and 13C NMR spectra of compound 16 [500 MHz for 1H and 125 MHz for 13C, CDCl3]. 
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Figure S18. 1H NMR spectra of compounds 17 and 18 [500 MHz, CDCl3]. 
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Table S3. Crystal data, data collection, and refinement details for compound 8 
Crystal data 
 C10H12O5 Z = 2 
Mr = 212.20 F(000) = 224 
Triclinic, P1 Dx = 1.491 Mg m–3 
a = 4.1747 (3) Å Mo Kα radiation, λ = 0.71073 Å 
b = 10.9965 (7) Å Cell parameters from 6326 reflections 
c = 11.0671 (7) Å θ = 3.8–30.0° 
α = 70.466 (1)° µ = 0.12 mm–1 
β = 85.814 (1)° T = 193 K 
γ = 80.816 (1)° Irregular, colourless 
V = 472.57 (5)  Å3 0.28 × 0.24 × 0.13 mm 
Data Collection 
Bruker APEX CCD diffractometer 5123 reflections with I > 2σ(I) 
Radiation source: fine-focus sealed X-ray tube Rint = 0.019 
Graphite monochromator θmax = 30.1°, θmin = 3.8° 
φ and ω scans h = –5→5 
8913 measured reflections k = –15→15 
5255 independent reflections l = –15→15 
Refinement 
 Refinement on F2 Hydrogen site location: mixed 
Least-squares matrix: full H atoms treated by a mixture of independent 
and constrained refinement 
R[F2 > 2σ(F2)] = 0.035  w = 1/[σ2(Fo2) + (0.0696P)2 + 0.0318P]   
where P = (Fo2 + 2Fc2)/3 
wR(F2) = 0.099 (∆/σ)max < 0.001 
S = 1.03 ∆〉max = 0.37 e Å–3 
5255 reflections ∆〉min = –0.20 e Å–3 
281 parameters Absolute structure:  It was not possible to 
unambiguously determine the absolute structure 
from X-ray data for this light atom structure. 
Results   for Flack x using 2407 quotients [(I+)–
(I–)]/[(I+)+(I–)] are given  (Parsons and Flack 
(2004), Acta Cryst. A60, s61). 
3 restraints Absolute structure parameter: 0.1 (3) 
Primary atom site location: structure-
invariant direct methods 
 
 
 
 
Table S4. Antimicrobial activities of compounds 1, 4-18   
_____________________________________________________________________________ 
Compound   Minimal Inhibitory Concentration (µg/mL) 
  S. aureus E. coli  M. smegmatis  C. albicans A. niger 
______________________________________________________________________________ 
1  > 203  > 203  > 203   > 203  203 
4  > 140  > 140  > 140   > 140  > 140 
5  > 25  > 25  > 25   > 25  > 25 
6  > 145  > 145  145   145  > 145 
7  > 155  > 155  > 155   > 155  > 155 
8  > 53  > 53  > 53   > 53  > 53 
9  > 55  > 55  > 55   > 55  > 55 
10  > 35  > 35  > 35   > 35  > 35 
11  > 25  25  25   25  > 25 
12  > 75  75  > 75   > 75  > 75 
13  > 75  > 75  > 75   > 75  > 75 
14  > 65  > 65  > 65   > 65  > 65 
15  > 100  > 100  > 100   100  >100 
16  > 75  > 75  > 75   > 75  > 75 
17   > 125  > 125  > 125   > 125  > 125 
18  > 98  > 98  > 98   > 98  > 98 
_______________________________________________________________________ 
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Figure S19. Phylogram of the most likely tree (-lnL = 7703.41) from a PHYML analysis of 37 
taxa based on ITS rDNA (1087 bp). Numbers refer to RAxML bootstrap support values ≥ 70% 
based on 1000 replicates. G100 and G012 are highlighted in gray. 21 d old cultures of both 
isolates are shown (A, G100, Clohesyomyces aquaticus); (B, G012, Clohesyomyces sp.) Bar 
indicates nucleotide substitutions per site. 
 
 
 
Figure S20. a–b. Conidia of Clohesyomyces aquaticus (G100); note arrow showing 
irregular mucilaginous sheath. Bars = 10 µm.  
 
